Showing 1 - 15 of 15 trials – Showing only trials currently accepting patients

• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  Stanford is currently accepting patients for this trial.

• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

  Stanford is currently accepting patients for this trial.

• Molecular Analysis of Thoracic Malignancies

  Stanford is currently accepting patients for this trial.

• A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

  Stanford is currently accepting patients for this trial.

• Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

  Stanford is currently accepting patients for this trial.

• MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

  Stanford is currently accepting patients for this trial.

• Expanded Access to Ensartinib for Participants With ALK+ NSCLC

  Stanford is currently accepting patients for this trial.

• Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  Stanford is currently accepting patients for this trial.

• Adjuvant Durvalumab for Early Stage NSCLC Patients With ctDNA Minimal Residual Disease

  Stanford is currently accepting patients for this trial.

• Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

  Stanford is currently accepting patients for this trial.

• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  Stanford is currently accepting patients for this trial.

• A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

  Stanford is currently accepting patients for this trial.

• Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

  Stanford is currently accepting patients for this trial.

• A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

  Stanford is currently accepting patients for this trial.

• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  Stanford is currently accepting patients for this trial.